Offstream
news

---

Changes

1. Sri Lanka receives 500,000 doses of Covishield (Oxford–AstraZeneca) vaccine from India.
   2021-02-26 01:05:41 (First version)
2. Sri Lanka receives 500,000 doses of the Oxford–AstraZeneca vaccine from India.
   (Current version)

---

Related

Nepal begins administering second doses of the Oxford-AstraZeneca vaccine dose for nearly 1.4 million elderly people following a months-long delay due to India suspending exports of vaccines due to a substantial increase in the number of cases there. The vaccines were donated by Japan and Bhutan.
2021-08-9

Sri Lanka approves the emergency use of the Pfizer–BioNTech COVID-19 vaccine as the country faces its third wave of the pandemic and the highest number of active cases since the pandemic began. The minister overseeing the situation says that Sri Lanka will try to secure five million doses of the vaccine as India has restricted the supply of the Oxford-AstraZeneca COVID-19 vaccine.
2021-05-8

Bhutan launches their largest vaccination campaign against COVID-19 using the Oxford-AstraZeneca vaccine that was received from India.
2021-03-27

Hungary grants emergency use approval for the CanSino Biologics Convidecia and Indian Covishield COVID-19 vaccines.
2021-03-22

Sri Lanka receives its first shipment of 264,000 doses of the Oxford–AstraZeneca vaccine supplied through the COVAX vaccine-sharing initiative.
2021-03-7

The Indian government announces that people can choose their COVID-19 vaccination centres when the vaccination campaign expands next week. This will allow people to choose whether they want to receive the Oxford–AstraZeneca vaccine or the Bharat Biotech vaccine.
2021-02-26

Mexico receives a shipment of 870,000 doses of the Oxford–AstraZeneca vaccine from India.
2021-02-14

Morocco receives their second shipment of four million doses of AstraZeneca's vaccine from India.
2021-02-11

Egypt receives its first shipment of 50,000 doses of the AstraZeneca vaccine from India.
2021-01-31

India approves the emergency use of the vaccine developed by the University of Oxford and AstraZeneca, becoming the third country in the world to do so after the United Kingdom and Argentina.
2021-01-1